TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)

TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $1,230.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst commented, "REGN/SNY reported that Study C for Dupi in CSU succeeded just like Study A with plans to resubmit by YE which could lead to an approval by H2:25. The very positive derm experience should carry over to CSU, and we conservatively estimate ~$700MM of sales by 2030. The company also reported impressive Dupi data in BP, a small indication without approved biologics, and anticipates filing by YE."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $1136.35 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker